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We conducted a high-throughput screen for small
molecule activators of the TRPML3 ion channel,
which, when mutated, causes deafness and pigmen-
tation defects. Cheminformatics analyses of the 53
identified and confirmed compounds revealed nine
different chemical scaffolds and 20 singletons. We
found that agonists strongly potentiated TRPML3
activation with low extracytosolic [Na+]. This syner-
gism revealed the existence of distinct and coopera-
tive activation mechanisms and a wide dynamic
range of TRPML3 activity. Testing compounds on
TRPML3-expressing sensory hair cells revealed the
absence of activator-responsive channels. Epider-
mal melanocytes showed only weak or no responses
to the compounds. These results suggest that
TRPML3 in native cells might be absent from the
plasma membrane or that the protein is a subunit of
heteromeric channels that are nonresponsive to the
activators identified in this screen.
INTRODUCTION
The TRPML subfamily of transient receptor potential (TRP) chan-
nels consists of the three proteins—TRPML1, TRPML2, and
TRPML3—which were initially described in the wake of the
discovery of the human mucolipin (TRPML1) gene as the cause
of Mucolipidosis Type IV (Bargal et al., 2000). The murine Trpml2
and Trpml3 genes (mucolipin 2 and 3) were identified in a posi-
tional cloning project to identify the gene responsible for the
murine varitint-waddler (Va) mutation (Di Palma et al., 2002). Ulti-
mately, a single A419P amino acid substitution within the pre-
dicted transmembrane domain 5 (TM5) of murine TRPML3 was
identified to cause the severe auditory, vestibular, and melano-
cyte phenotype: variegated coat color, circling behavior, deaf-
ness, and perinatal lethality observed in Va/Va homozygotes
(Di Palma et al., 2002). The A419P substitution renders TRPML3
constitutively active (Grimm et al., 2007; Kim et al., 2007; Nagata
et al., 2008; Xu et al., 2007), which has led to the hypothesis that
constitutive activity leads to calcium overload and apoptotic cellChemistry & Biology 17, 135death in cells that natively express TRPML3, such as melano-
cytes and sensory hair cells (Grimm et al., 2007, 2009; Kim
et al., 2007; Nagata et al., 2008; Xu et al., 2007). Heterologously
expressed TRPML3 displays currents that are inwardly rectified
and regulated by extracellular [H+] and [Na+] (Kim et al., 2007;
Kim et al., 2008). It has been hypothesized that luminal pH affects
TRPML3 activity (Kim et al., 2008). Despite progress in charac-
terizing wild-type and mutant TRPML3 isoforms, the physiolog-
ical roles of this TRP ion channel remain unknown.
Selective ligands and activators are playing major roles in
characterizing the physiological roles of many TRP channels. In
contrast to the increasing number of ligands, activators, and,
recently, antagonists for many TRP channels (for reviews see
Patapoutian et al., 2009 and Ramsey et al., 2006), there are
neither activators nor selective inhibitors known for members
of the TRPML subfamily. A reasonable and efficient approach
to identify small molecule ion channel modulators is through
compound library screening. In this report, we describe the iden-
tification of the first selective small molecule TRPML3 activators
by high-throughput screening. Maximal activation capability of
the different compounds ranged from only a fraction to up to
two times higher than the activity of the TRPML3 Va mutant
channel isoform. Low extracellular sodium had a strong syner-
gistic effect on compound activation, extending the activity
range of TRPML3 over two orders of magnitude. Using the iden-
tified agonists as tools, we sought to activate TRPML3 in native
cell types, such as sensory hair cells and melanocytes. Only one
compound was able to elicit weak calcium influx into primary
epidermal melanocytes, and none of the compounds was effec-
tive on neonatal cochlear hair cells. This surprising discrepancy
between heterologous expression and native cells suggests that
TRPML3 channels are either largely absent from the plasma
membrane of hair cells and melanocytes, or that plasma mem-
brane localization of the channel is being tightly regulated, or
alternatively, that TRPML3 in melanocytes and hair cells contrib-
utes to heteromeric channels that lack responsiveness to the
activators.RESULTS
High-Throughput Screen Reveals TRPML3 Activators
To identify compounds that elicit a TRPML3-specific increase of
[Ca2+]i, we conducted two parallel high-throughput screens with–148, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 135
Figure 1. TRPML3-Activating Compounds
(A) Correlation plot for TRPML3 and TRPN1 high-throughput screens. Molecules found to be TRPML3-selective agonists are displayed as red triangles.
Compound activity is normalized to the maximum carbachol response. Vertical and horizontal lines represent the hit cutoff values of the TRPML3 (11.46%)
and TRPN1 (18.88%) screens.
(B) [Ca2+]i increases of HEK293 cells transiently expressing human (h) TRPML3, or control TRP channels in response to application of 10 mM of selected
compounds. TRPML1(NC) is a TRPML1 variant that is localized to the plasma membrane (see Figure 7A–C). For details and responses to compounds from
all scaffold groups, see Figure S1.
(C) Steady-state current-voltage plots of whole-cell currents elicited in HEK293 cells transiently transfected with human TRPML3 or YFP (negative control) after
perfusion with compounds SF-11, SF-22, and SN-2 (10 mM in standard bath solution). For details and responses to compounds from all scaffold groups, see
Figure S2.
(D) Bar diagram shows average inward current densities at80 mV of TRPML3-expressing HEK293 cells before (no compound) and after compound application
(+ compound). Cells transfected with the constitutively active human TRPML3(A419P) isoform (green) were used as positive controls, and cells transfected with
YFP were used as negative controls. In general, three bars are shown for each test series (no compound and with compound on TRPML3-expressing cells and
with compound on YFP-expressing cells). For compounds SF-11, SF-22, and SN-2, we tested intracellular application (infusion), resulting in a fourth bar, shown
and indicated in amber. Compound SF-11 elicited responses when applied intracellularly, which indicates that this molecule is either cell membrane permeant or
that it is able to act on distinct intra- and extracellular activation sites. Compounds SF-22 and SN2 did not elicit a response when infused into the cells, indicating
that the compounds act exclusively extracellularly, and suggesting that the compounds are not cell membrane permeable. The control compound probenicid did
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protein. The screening conditions for high-throughput calcium
flux screening, with Fluo-8 calcium indicator dye, were optimized
to give the best balance between assay performance, reagent
consumption, and suitability of the protocol for robotic-based
screening (see Experimental Procedures). This process estab-
lished precisely matched conditions for both screening cam-
paigns. A total of 217,969 compounds were tested at a single
concentration of approximately 3 mM. Compounds that activated
TRPML3 or TRPN1 greater than the mean response plus three
standard deviations (the hit cutoff) for the entire compound
data set were considered as hits. A total of 632 compounds
met this criterion for the TRPML3 campaign. Comparison to
the TRPN1 control campaign established 300 compounds com-
mon to both campaigns (Figure 1A). Removal of overlapping
hits left 332 TRPML3-selective agonist candidates. Triplicate
retesting using the same assay conditions as the original screen
confirmed 244 compounds with activity greater than the hit
cutoff. Counter testing using TRPN1-expressing HEK293 cells
revealed that 29 of these 244 candidates were active and, there-
fore, nonselective for TRPML3. Twenty-seven compounds were
unavailable for further testing, which left 188 candidates for
which dose-response relationships were determined over a
range from 29.9 mM to 1.5 nM. Compounds chosen for further
evaluation had an EC50 value of less than 3 mM for TRPML3
and greater than 29.9 mM for TRPN1, amounting to a R10-fold
preference for TRPML3. Fifty-three compounds met these cri-
teria (see Tables S1 and S2 available online). Cheminformatics
analyses placed the 53 activators into nine chemical scaffolds
(SF) and 20 singletons (i.e., compounds sharing no structural
resemblance within all other dosed compounds). The nine
chemotypes identified were (pyrazol-5-yl)isoxazole-benzenesul-
fonamides (SF-1), secondary arylsulfonamides (SF-2), tertiary
arylsulfonamides (SF-3), sulfonylarylpiperazines (SF-4), 1-(2,2,4-
trimethylquinolinyl)-alkylones (SF-5), spirobenzoannulene-arylpyr-
azolones (SF-6), t-butyl-3-methyl-4-(arylsulfonyl)-pyrazol-5-ols
(SF-7), arylsulfonylpyridin-2-ones (SF-8), and t-butyl-3methyl-
furan-2-carboxamides (SF-9).
Different Compounds Have Distinct TRPML3
Activation Profiles
For further evaluation in alternative assays, we selected at
least one representative of each chemical scaffold and two
singletons, SN-1 and SN-2. Criteria for this selection were low
EC50 values for TRPML3 activation, low activation of TRPN1,
and compound availability. SF-9 compounds were not tested
because they were not commercially available. In total, 15 com-
pounds were obtained from commercial vendors, verified by
liquid chromatography-mass spectrometry, and reconfirmed in
TRPML3 and TRPN1 activation assays. All 15 compounds
confirmed activity in the TRPML3 assay with EC50 values ofnot activate TRPML3. Statistical comparisons of means were made using one-wa
theses are the number of cells analyzed). ***p < 0.0001, **p < 0.001, and *p < 0.0
(E) Continuous sample traces demonstrate spontaneous TRPML3 single channel o
‘‘C’’ indicates the closed level of the traces.
(F) A representative outside-out patch recording is seen, illustrating the effect
The patches were held at 80 mV. The compound was applied, as indicated b
from the same patch obtained before the application of SF-22.
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and SN-1, the EC50 values were less than 1 mM (Table 1). Only
compounds SF-21 and SF-51 exhibited significant activity
against TRPN1. Both compounds were more active when tested
from powders, which may reflect some minor decomposition in
the high-throughput screening samples, which are stored as
liquids.
The 15 compounds were further evaluated in calcium imaging
and patch-clamp electrophysiology experiments. Selectivity
was tested using HEK293 cells transfected with expression
vectors for TRPML3, TRPML2, TRPML1, TRPM2, TRPV2,
TRPC3, TRPN1, and TRPA1. All tested compounds elicited
strong increases of intracellular calcium in TRPML3-transfected
cells using fura-2 as the calcium indicator dye (Figure 1B;
Figure S1). The strongest responses, amounting to R1.5-fold
increase in the 340 nm/380 nm ratio, were obtained with com-
pounds SF-21, SF-22, SF-23, SF-31, SF-41, SN-1, and SN-2.
We also observed that compounds SF21, SF-41, and SN-2
elicited a much more rapid increase than did the other com-
pounds, with SF-33 and SF-51 displaying the slowest kinetics.
The benzosulfonamide probenicid (4-(dipropylsulfamoyl)ben-
zoic acid), a compound structurally similar to several of the scaf-
folds identified by high-throughput screening, was used as
negative control and did not elicit any responses (data not
shown).
Three compounds, SF-21, SF-41, and SF-81, also elicited
responses in HEK293 cells expressing TRPML2 (Figure S1). In
contrast, no responses were observed in cells expressing
TRPML1, which is not surprising because TRPML1 is predomi-
nantly located in lysosomes. When we tested the compounds
on the mutant TRPML1(NC) isoform that is present in the plasma
membrane (see below for details), we found that compound
SF-22 was able to activate this channel. None of the compounds
substantially activated any of the other TRP channels tested.
The nonspecific responses of some compounds observed on
TRPML2 and TRPML1(NC) confirmed that these two channels
are localized in the plasma membrane of transfected HEK293
cells.
Whole-cell patch-clamp experiments revealed inwardly recti-
fying currents in TRPML3-transfected cells for all compounds,
with average current densities between 20 and 600 pA/pF at
80 mV (Figure 1C; Figure S2). No significant currents were
detectable in cells transfected with YFP only, or in cells express-
ing unrelated channels, such as TRPV2 or TRPA1 (data not
shown). Average current densities in TRPML3 transfected cells
perfused with compounds SF-22, SF-23, SF-31, SF-81, SN-1,
and SN-2 were comparable to average current densities
obtained from cells expressing the constitutively active varitint-
waddler mutant isoform A419P of TRPML3 (Figure 1D) (Grimm
et al., 2007). Stronger responses were obtained with compounds
SF-21, SF-41, and SF-51. The combined results of they ANOVA followed by Tukey’s post test (mean values ± SEM, number in paren-
1.
penings in an outside-out patch in the absence of the small molecule activator.
of compounds SF-22 on the activity of TRPML3 expressed in HEK293 cells.
y the bar. The inset below the recording shows the expanded sample trace
–148, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 137
Table 1. Summary of Data for the 15 TRPML3-Selective Activators
Compound ID (chemical name)
Max %
Activation
(TRPML3)
Max %
Activation
(Control)
EC50 (mM)
(TRPML3)
EC50
(mM)
(Control)
DF340/F380
(TRPML3)
DF340/F380
(Control)
nA/pF
(80 mV)
(TRPML3)
nA/pF
(80 mV)
(Control)
SF-11
(3-(4-chlorophenyl)-5-methyl-4-
[2-(4-methylphenyl)sulfonylpyrazol-
3-yl]-1,2-oxazole)
135 ± 20 8 ± 1 0.26 ± 0.04 >29.9 0.72 ± 0.05 0.005 ± 0.002 0.14 ± 0.02 0.004 ±
0.001
SN-1
(N-tert-butyl-3-(3-tert-butyl-1-
methyl-7-oxo-4H-pyrazolo[4,3-
d]pyrimidin-5-yl)-4-
ethoxybenzenesulfonamide)
151 ± 14 6 ± 0 0.88 ± 0.06 >29.9 1.15 ± 0.06 0.005 ± 0.004 0.33 ± 0.10 0.005 ±
0.001
SF-21
(4-chloro-N-(2-morpholin-4-yl
cyclohexyl)benzenesulfonamide)
200 ± 7 61 ± 2 0.45 ± 0.04 14.24 ±
2.03
1.38 ± 0.10 0.033 ± 0.008 0.55 ± 0.08 0.003 ±
0.001
SF-22
(5-chloro-N-(2-piperidin-1-yl
phenyl)thiophene-2-sulfonamide)
156 ± 16 1 ± 0 0.66 ± 0.06 >29.9 1.00 ± 0.07 0.082 ± 0.014 0.24 ± 0.06 0.004 ±
0.001
SF-31
(1-(4-ethoxynaphthalen-1-yl)
sulfonylazepane)
130 ± 20 2 ± 1 0.99 ± 0.23 >29.9 1.00 ± 0.10 0.011 ± 0.001 0.19 ± 0.03 0.003 ±
0.001
SF-23
(5-chloro-N-(2-morpholin-4-yl
phenyl)thiophene-2-sulfonamide)
174 ± 1 1 ± 1 1.10 ± 0.15 >29.9 0.93 ± 0.07 0.005 ± 0.005 0.37 ± 0.08 0.005 ±
0.001
SF-41
(1-(2,4-dimethylphenyl)-4-
piperidin-1-yl sulfonylpiperazine)
138 ± 12 12 ± 1 2.11 ± 0.69 >29.9 0.99 ± 0.07 0.015 ± 0.001 0.42 ± 0.07 0.007 ±
0.002
SF-51
(2-[2-oxo-2-(2,2,4-
trimethylquinolin-1-yl)
ethyl]isoindole-1,3-dione)
175 ± 18 47 ± 3 0.93 ± 0.20 >29.9 0.78 ± 0.03 0.007 ± 0.005 0.41 ± 0.10 0.016 ±
0.008
SF-32
(1-(4-ethoxy-2,3-dimethylphenyl)
sulfonylpiperidine)
119 ± 5 2 ± 1 1.81 ± 0.14 >29.9 0.52 ± 0.05 0.008 ± 0.005 0.02 ± 0.01 0.003 ±
0.001
SF-24
(4-methyl-N-(2-phenylphenyl)
benzenesulfonamide)
86 ± 7 2 ± 0 2.41 ± 0.87 >29.9 0.51 ± 0.05 0.016 ± 0.023 0.02 ± 0.01 0.003 ±
0.001
SF-33
(5-chloro-N,N-diethyl-4-methyl-
2-propoxybenzenesulfonamide)
119 ± 21 2 ± 1 4.79 ± 1.09 >29.9 0.65 ± 0.10 0.007 ± 0.016 0.06 ± 0.02 0.003 ±
0.001
SN-2
(5-mesityl-3-oxa-4-azatricyclo
[5.2.1.02,6]dec-4-ene)
149 ± 11 3 ± 1 1.13 ± 0.16 >29.9 1.08 ± 0.05 0.024 ± 0.012 0.30 ± 0.07 0.009 ±
0.003
SF-61
(4-(2-methoxyphenyl)spiro[3,4-
dihydropyrazole-5,80-6,7-
dihydro-5H-benzo[7]annulene]-
90-one)
102 ± 22 2 ± 1 3.74 ± 1.02 >29.9 0.56 ± 0.03 0.005 ± 0.006 0.07 ± 0.01 0.002 ±
0.001
SF-71
([2-tert-butyl-5-methyl-4-(4-
methylphenyl)sulfonylpyrazol-3-yl]
butanoate)
85 ± 8 2 ± 1 2.52 ± 0.83 >29.9 0.75 ± 0.06 0.002 ± 0.004 0.08 ± 0.02 0.012 ±
0.006
SF-81
(4,6-dimethyl-3-(2-methylphenyl)
sulfonyl-1-propan-2-yl pyridin-2-one)
138 ± 21 1 ± 0 2.29 ± 0.19 >29.9 0.62 ± 0.05 0.005 ± 0.016 0.20 ± 0.03 0.002 ±
0.001
Maximum activation is shown in percentage, normalized to the maximum carbachol responses, and EC50 values are reported as mean values ± SD
(n = 3). Controls for activation and EC50 are TRPN1-expressing HEK293 cells. Fura-2 (DF340/F380) and patch-clamp data (nA/pF) are mean values ±
SEM (nR 3). Controls for calcium imaging and patch-clamp experiments are YFP-expressing HEK293 cells.
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Figure 2. Effects of Extracellular Sodium on
TRPML3
(A) Average steady-state current-voltage plots of
whole-cell currents elicited in HEK293 cells
expressing murine TRPML3 before and after perfu-
sion with extracellular solution containing 2 mM
NaCl, 150 mM KCl, 0.25 mM CaCl2, 10 mM HEPES,
and 10 mM D-glucose (pH 7.4) (endolymph-like
solution [ELS]). Standard bath solution (SBS) con-
tained 138 mM NaCl, 5.4 mM KCl, 2 mM MgCl2,
2 mM CaCl2, 10 mM HEPES, and 10 D-glucose
(pH 7.4). The major cation in the pipette solution
was 150mM Cs+ (pH 7.2). Currents elicited with
extracellular ELS in nontransfected HEK293 cells
(NT) are depicted in gray.
(B) Average inward current densities of the experi-
ments in (A) at 80 mV and 200 mV.
(C) Average steady-state current-voltage plots of
whole-cell currents inpresence ofextracellular solu-
tion containing either 150 mM KCl, LiCl, CsCl, or
NMDG-Cl (0 Ca2+, 0 Mg2+, 0 Na+). The major cation
in the pipette solution was 150 mM Cs+ (pH 7.2).
(D) Average inward current densities of the experi-
ments in C at 80 mV and 200 mV.
(E) ‘‘Dose-response’’ curve obtained from currents measured as described in A in different sodium and potassium concentrations corresponding to mouse
endolymph composition during neonatal inner ear maturation (SBS = 138 mM NaCl and 5.4 mM KCl; S1 = 40 mM NaCl and 110 mM KCl; S2 = 20 mM NaCl
and 130 mM KCl; S3 = 5 mM NaCl and 145 KCl; and S4 = 2 mM NaCl and 150 mM KCl).
(F) Average inward current densities before and after perfusion with ELS at 80 mV and 200 mV. The major cation in the pipette solution was either K+ or Na+
(150 mM [pH 7.2]), as indicated. Shown are mean values ± SEM (n= parenthesized). Statistical comparisons of means were made using one-way ANOVA followed
by Tukey’s post test; ***p < 0.0001, **p < 0.001, and *p < 0.01.
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studies, as well as the whole-cell patch-clamp data are summa-
rized in Table 1.
Excised patch experiments were performed to further confirm
the ability of selected compounds (SF-22, SF-23, and SN-2) to
activate TRPML3. In general, channel density was too high to
clearly distinguish single channels, but the recordings confirmed
that the tested compounds markedly increased TRPML3 activity
(Figures 1E and 1F). We estimate that the conductance of
TRPML3 channels, when activated with 10 mM SN-2, is approx-
imately 10 pS at 80 mV, which is comparable to previously
observed values (Xu et al., 2007).
In summary, all 15 candidate compounds identified in the
high-throughput screen were able to activate TRPML3. Dif-
ferences between the compounds include different maximal
response levels and different apparent activation kinetics, as
well as some of the compounds being able to activate the related
TRPML1 and TRPML2 channels.
Low Extracellular Na+ Concentration Increases
the Open Probability of TRPML3 and Potentiates
Compound Effects
Recently, it has been shown that high extracellular sodium has
an inhibitory effect on the activity of wild-type TRPML3 (Kim
et al., 2008). This is an intriguing finding because, in the inner
ear, TRPML3 is transiently detectable at the base of mouse
cochlear hair cell stereocilia between postnatal days 2–6
(P2-P6). Between P6 and P10, the protein is down-regulated and
at P10, it is no longer detectable in the apical hair cell membrane
by immunocytochemistry (Atiba-Davies and Noben-Trauth,
2007; van Aken et al., 2008). The transient expression of TRPML3
in stereocilia correlates with a critical period of organ of CortiChemistry & Biology 17, 135maturation in which hair and supporting cells acquire their
mature cytomorphologies, hair cells become mechanosensitive
(Waguespack et al., 2007), and afferent and efferent innervation
assume their adult patterns (Simmons et al., 1996). Likewise,
the extracellular solution of the scala media, the endolymph,
acquires its typical composition of low Na+ (from 36 mM at P1,
to 4.1 mM at P5, to 2.8 mM in the adult mouse) and high K+
(from 104 mM at P1, to 136 mM at P5, to 202 mM in the adult)
(Yamasaki et al., 2000). In particular, the changes in endolymph
composition during a period of strong TRPML3 expression in the
hair bundle spurred our interest to investigate whether TRPML3
displays altered activity when exposed to endolymph-like solu-
tions in comparison with standard bath solution.
We found that, in the presence of endolymph-like extracellular
solution (ELS) with high K+ (150 mM) and low Na+ (2 mM),
TRPML3-expressing HEK293 cells showed a robust inwardly
rectifying current (Figures 2A and 2B) that was not detectable
when the cells were exposed to standard bath solution (SBS)
containing high Na+ (138 mM). Extracellular solution containing
either K+ or Li+ as the sole cation (at 150 mM) evoked currents
of comparable sizes in wild-type TRPML3-expressing HEK293
cells (Figures 2C and 2D). Peak currents at 200 mV varied
between 100 pA/pF and 130 pA/pF. Extracellular solution con-
taining 150 mM Cs+ resulted in significantly smaller inward
currents, with peak currents at 200 mV of about 50 pA/pF.
TRPML3 was impermeable to the organic monovalent cation
N-methyl-D-glucamine (NMDG+). Because the composition of
endolymph is changing during development (Yamasaki et al.,
2000), we tested different solutions (S1–S4) containing varying
concentrations of K+ and Na+. Solutions S1–S4 correspond to
the potassium and sodium concentrations obtained from P1,
P3, P5, and adult mouse endolymph (Yamasaki et al., 2000).–148, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 139
Figure 3. Low Extracellular Sodium Potentiates
Agonist Effects on TRPML3
(A) Representative steady-state current-voltage plots of
whole-cell currents before and after perfusion with
compound SF-24 alone (10 mM), compound SF-24 +
ELS, and with ELS alone.
(B) Average inward current densities at 80 mV of exper-
iments as shown in (A), normalized by cell capacitance
(pF). Shown are mean values ± SEM (n = number of cells
analyzed).
(C and D) Same experiments as described in (A and B) with
singleton compound SN-2 (10 mM), holding potential =
+10 mV, voltage steps between 80 mV and + 80 mV.
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decreasing sodium and increasing potassium concentrations
(Figure 2E).
An increase of calcium (up to 2 mM) or adding magnesium
(2 mM) to ELS did not significantly change the previously
observed effects. Likewise, omission of divalents in SBS had
no effect. Increasing the BAPTA concentration in the pipette
solution from 1 mM to 10 mM also had no significant effect
(data not shown). These results are consistent with the finding
that TRPML3 activity depends on the extracellular Na+ concen-
tration, as reported elsewhere (Kim et al., 2008). TRPML3 is
closed at the physiologically high extracellular Na+ concentration
of 138 mM (SBS), but it shows increased open probability when
[Na+] falls below 20 mM.
To determine whether changes in the intracellular ionic
composition interfere with the activity of TRPML3, we replaced
the cesium-containing pipette solution with solutions containing
150 mM K+ or 150 mM Na+, respectively. With either ion, we
observed no significant differences in the current densities eli-
cited by ELS (peak currents between 100 pA/pF and 130 pA/
pF at 200 mV), compared with measurements with cesium
inside the patch pipette (Figure 2F). These results show that, in
contrast to high extracellular sodium, high intracellular sodium
does not block TRPML3 activity.
We next investigated the relationship between activation
with ELS and activation with compound activators. We perfused
TRPML3-expressing HEK293 cells with a series starting with
compound alone (in SBS), with compound in ELS, and finally
with ELS alone. Two representative compounds, SF-24 and
SN-2, were tested. SF-24 is one of the least effective com-
pounds, and SN-2 is one of the most active ones. Combining
SF-24 with ELS had a strong synergistic effect on TRPML3 acti-
vation, resulting in up to 10-fold increases in current densities,
when compared to ELS alone or SF-24 in SBS (Figures 3A and
3B). SN-2 had a similar synergistic effect, also reaching up to
10-fold enhancement of the combined response when com-
pared with the individual responses, reaching average current
densities of up to 3 nA/pF at 80 mV (Figures 3C and 3D).140 Chemistry & Biology 17, 135–148, February 26, 2010 ª2010 Elsevier Ltd All rightsCochlear Hair Cells Expressing TRPML3
Do Not respond to ELS and Compound
Activators
Neonatal hair cells express TRPML3, and the
channel protein is detectable in mouse cochlear
hair cell stereocilia during the first weeks afterbirth (Di Palma et al., 2002; van Aken et al., 2008). In varitint-
waddler mutant hair cells, constitutively active TRPML3 leads
to calcium loading and death of cochlear hair cells, which
suggests that at least a subpopulation of TRPML3 channels
are located in the plasma membrane of hair cells (Grimm et al.,
2007, 2009; Kim et al., 2007; Nagata et al., 2008; Xu et al.,
2007). This expression in vivo raised the question whether ELS
or compound activators or combinations of both are able to acti-
vate TRPML3 in native hair cells. We acutely isolated P5-P6 rat
organ of Corti and we tested their response to ELS, and SF-21
or SN-2 in SBS, as well as SN-2 in ELS. Neither compound at
concentrations of up to 100 mM, with or without endolymph-
like extracellular solution, elicited TRPML3 channel activity in
cochlear hair cells (Figure S3). Mechanotransduction currents
in all cells tested were unperturbed by ELS or compound expo-
sure, or combinations of both (data not shown).
Epidermal Melanocytes Expressing TRPML3 Show
No or Only Small Responses to Compound Activators
The varitint-waddler phenotype also revealed that melanocytes
of the epidermis express mutant TRPML3 in the plasma
membrane, leading to calcium loading and cell death (Di Palma
et al., 2002). We examined primary human epidermal melano-
cytes, which express all three TRPML channels (Figure 4A),
and we tested compounds at concentrations up to 100 mM.
The compounds elicited no or very small responses, with the
exception of SN-2, which, when applied at concentrations of
30 mM and 100 mM, elicited a stronger response (Figure 4B).
NIH 3T3 cells, which do not express TRPML3 natively (Fig-
ure 4C), were used as a negative control, and none of the
compounds tested at 100 mM elicited a response (Figure 4D).
When we overexpressed TRPML3 in melanocytes, we detected
strong increases of [Ca2+]i after compound application, similar to
the responses observed in HEK293 cells (Figure 4E). Overex-
pression of TRPML3 in NIH 3T3 cells resulted in responses
comparable to the effects of compounds on TRPML3-express-
ing HEK293 cells or melanocytes overexpressing TRPML3
(Figure 4F).reserved
Figure 4. Compound Effects on Epidermal Skin Melanocytes
(A) RT-PCR shows robust expression of TRPML1 (500 bp), TRPML2 (411 bp), TRPML3 (487 bp), and GAPDH control (444 bp) in primary human epidermal mela-
nocytes (HEM).
(B) Ca2+-imaging results showing changes of [Ca2+]i in HEM in response to application of TRPML3-activating compounds at concentrations of 100 mM (mean
values ± SEM; nR 3 independent experiments with 20–30 cells). Responses to SN-2 are shown for 30 mM (gray bar) and 100 mM.
(C) RT-PCR demonstrating presence of TRPML1 (470 bp) and GAPDH (442 bp) transcripts in NIH 3T3 cells, but not TRPML2 (500 bp) and TRPML3 (550 bp).
(D) Ca2+-imaging experiments as described in (B) showing compound effects (at 100 mM) on NIH 3T3 cells.
(E) Ca2+-imaging experiments showing [Ca2+]i increases in HEM transfected with human TRPML3-YFP or nontransfected cells (NT) upon application of SF-22 and
SN-2 at 100 mM.
(F) Ca2+-imaging experiments as described in (E) showing compound effects on NIH 3T3 cells transfected with human TRPML3-YFP or NT.
(G) Ca2+-imaging experiments on HEK293 cells expressing TRPML3 and dominant negative TRPML3(D458K) or TRPML2 as a control. Shown are responses to
compounds SF-21 and SN-2.
(H) SN-2-elicited changes of [Ca2+]i in HEM transfected with expression vectors for TRPML3, dominant negative TRPML3(D458K), and YFP control. NT, nontrans-
fected control cells.
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plasma membrane of hair cells and is also largely absent from the
plasma membrane of primary melanocytes, or that the channel
might be in a state that renders it nonresponsive to mostChemistry & Biology 17, 135compounds. The effect of SN-2 on melanocytes raised the ques-
tion whether this compound acts nonspecifically, which would
be surprising because it did not show any activity on other
TRP channels, not even the related TRPML2 and TRPML1(NC)–148, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 141
Figure 5. InteractionsBetweenDifferentTRPMLChannels
(A) Confocal images of HEK293 cells expressing human TRPML3-
YFP or -CFP as well as human TRPML1-YFP or -CFP. White
arrows indicate plasma membrane and red arrows indicate intra-
cellular protein aggregations.
(B) Surface biotinylation experiment showing human TRPML3-YFP
in the plasma membrane. L = input load (1% of total), E = elution
from streptavidin beads. Surface-biotinylated YFP-tagged
TRPML3 was visualized with anti-GFP antibody (Clontech, JL8).
(C) Subcellular localization of human TRPML3-YFP when
coexpressed 1:1 with human TRPML1-CFP in HEK293 cells and
vice versa.
(D) Biotinylation experiments showing human TRPML3-YFP
(arrow) coexpressed with either human TRPML1 1:1 or empty
vector control in HEK293 cells visualized with anti-GFP antibody
in western blot.
(E) Relative surface biotinylation of TRPML3 coexpressed with
TRPML1 in percentage (mean ± SEM, n = 4). Cotransfections
with empty vector were set to 100%.
(F) Fluorescence energy resonance transfer (FRET) experiments
showing average FRET efficiencies between TRPML homo- and
heteromers. FRET efficiencies were determined by measuring
the recovery of CFP fluorescence during YFP photobleaching.
Cells were excited at 410 nm and 515 nm for CFP and YFP detec-
tion, respectively. YFP was bleached with an illumination at 512 nm
for 2.2 s.
(G) Average FRET efficiencies reported as mean values ± SEM
(n = parenthesized). ***p < 0.0001 and **p < 0.001, Student’s
t test, unpaired, comparison with TRPC6/TRPML3 coexpression
as negative control. All scale bars = 15 mm.
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ure 1D), we argue that its action on melanocytes is based on
an interaction with an extracellular site. To further investigate
this, we utilized the dominant negative TRPML3(D458K) mutant
(Kim et al., 2009), which completely eliminates responses to
activators when coexpressed with TRPML3 in HEK293 cells
(Figure 4G). Dominant negative TRPML3(D458K) was highly
effective in eliminating SN-2-induced activity in epidermal mela-
nocytes (Figure 4H), suggesting that SN-2 activates a channel
that is not responsive in presence of TRPML3(D458K). Such
a dominant negative action might be attributed to potential
heteromerization of TRPML3(D458K) with an SN-2-responsive
channel. Although in a different context, heteromerization of
TRPML channels has previously been postulated (Kim et al.,
2009; Venkatachalam et al., 2006; Zeevi et al., 2007, 2009), and
particularly TRPML1 has been put forward as a regulator of the
plasma membrane concentration of TRPML3 (Venkatachalam
et al., 2006), although the physiological relevance of this in vitro
observation is very much dependent on the circumstances, cell
type, and perhaps other unknown factors (Kim et al., 2009).
TRPML Channels Form Heteromers
Coexpression of TRPML1 strongly decreases compound
responsiveness of TRPML3 in transfected HEK293 cells. To142 Chemistry & Biology 17, 135–148, February 26, 2010 ª2010 Elsevier Ltd Alconfirm the previously postulated in vitro trafficking
effects of TRPML1 on TRPML3, and to demonstrate
that these effects are indeed the result of heteromeri-
zation, we differentially tagged the two proteins with
YFP and CFP. HEK293 cells transiently transfected
with TRPML1-YFP or -CFP and TRPML3-YFP or -CFPalone showed predominant expression of TRPML1 in intra-
cellular compartments, whereas TRPML3 was detected in intra-
cellular vesicles as well as in the plasma membrane (Figure 5A).
Plasma membrane localization of TRPML3 in transfected
HEK293 cells was confirmed by surface biotinylation, pull
down of biotinylated proteins, and western blot (Figure 5B).
When TRPML1 was coexpressed with TRPML3, the subcellular
localization of TRPML3 changed: more overexpressed TRPML3
protein was visible in intracellular compartments where it over-
lapped with TRPML1. Nearby cells that did not express TRPML1
still showed plasma membrane localization of TRPML3 (Fig-
ure 5C). In addition, surface biotinylation experiments revealed
a relative decrease of TRPML3 plasma membrane expression
in cells coexpressing both proteins, compared with control
experiments with empty vector cotransfection. The amount of
TRPML3 in the plasma membrane, when cotransfected with
control vector, was 25.8 ± 4.2% (mean ± SEM) of total TRPML3
protein (n = 3). Coexpression of TRPML1 decreased the amount
of TRPML3 detectable in the plasma membrane by 44.7 ± 16.0%
(mean ± SEM; n = 4) (Figures 5D and 5E). These results show that
TRPML1 coexpression is able to reduce the amount of TRPML3
protein in the plasma membrane of HEK293 cells. Because not
all cells are transfected equally and surface biotinylation aver-
ages across all cells, it is clear that this experiment only providesl rights reserved
Figure 6. Coexpression of TRPML1 with TRPML3 Decreases Activa-
tion Effect of TRPML3 Agonists in Transfected HEK293 Cells
(A–D) Ca2+-imaging measurements of [Ca2+]i changes in HEK293 cells coex-
pressing TRPML3 with either TRPML1, TRPML2 (control), TRPV2 (control),
or expression of TRPM1 alone in response to compounds SF-21, SF-22,
SF-23, or SN-2 (10 mM). Shown are mean values ± SEM (nR 3 independent
experiments with 20–30 cells each).
(E and F) representative steady-state current-voltage plots of whole-cell
currents. Currents were elicited in HEK293 cells coexpressing TRPML3-YFP
with either TRPML1-HA or TRPV2-HA (control) before and after perfusion
with selected compounds (10 mM in SBS).
(G) Average inward current densities at 80 mV and 200 mV of experiments
shown in (E and F).
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TRPML1 and TRPML3 in this heterologous expression system.
To demonstrate that these effects are caused by direct inter-
action of the two proteins (i.e., heteromerization), we performed
fluorescence resonance energy transfer (FRET) experiments
with the respective TRPML-CFP and -YFP fusion proteins. We
measured average FRET efficiencies between 13% and 20%
for TRPML homomers and heteromers, indicative of close
proximation of the two fluorophores (Figures 5F and 5G). FRET
effects between TRPC6 and TRPML3 showing an average
FRET efficiency of 5% were regarded as nonspecific and
comprised our negative control. TRPC6 homomers displayed
an average FRET efficiency of 17%. This finding is in accordance
with FRET efficiencies previously described for heteromeric
TRPML channels and TRPC6 (Hofmann et al., 2002; Venkata-
chalam et al., 2006). Overall, these results show that all TRPML
channels are able to heteromerize with each other. Although
these findings are based on overexpression studies, we believe
that heteromerization could be happening in cells and tissues
where the different TRPML channels are coexpressed (Fig-
ure S4), although coexpression does not necessarily mean that
the channels are targeted to the same subcellular locations
(Kim et al., 2009; Zeevi et al., 2009).
On the basis of this confirmation of TRPML1 and TRPML3
interactions, we tested whether coexpressed TRPML1 affects
the ability of TRPML3 to respond to compound activation.
With all four compounds tested (SF-21, SF-22, SF-23, and
SN-2), we observed a strong reduction of the calcium imaging
responses when TRPML1 was coexpressed (Figures 6A–6C).
Coexpression of TRPML2 or TRPV2 did not show any decrease
of TRPML3 responsiveness. Whole-cell patch-clamp recordings
confirmed these results (Figures 6E–6G). Interestingly, TRPML1
was not able to suppress the constitutively active TRPML3 var-
itint-waddler mutant isoforms Va and VaJ. Coexpression of these
isoforms with TRPML1 in a ratio 1:1 and even 1:5 still revealed
highly elevated intracellular calcium levels (Figure S5). This result
suggests that in varitint-waddler animals, mutant TRPML3 chan-
nels might be mislocalized to the plasma membrane as a result of
the inability of TRPML1 to affect trafficking. The mechanism of
this effect, however, is not clear.
We further investigated the effect of TRPML1 on trafficking of
TRPML3 by making use of TRPML1 mutants that locate to the
plasma membrane instead of endosomes/lysosomes. This can
be achieved by removal of both TRPML1-specific dileucine
motifs (lysosomal targeting sites [LTSs]) in the N and C termini
(Miedel et al., 2006; Venkatachalam et al., 2006; Vergarajauregui
and Puertollano, 2006) (Figures 7A and 7B). The resulting
TRPML1(NC) mutant isoform is expressed in the plasma mem-
brane (Figure 7C) where it can be activated by compound
SF-22 (Figure 1B), which is not cell permeable (Figure 1D). These
results show that TRPML1(NC) is at least partially targeted to the
plasma membrane and that the channel is functional.
Accordingly, coexpression of TRPML3 with TRPML1(NC)
should result in a smaller reduction of TRPML3 responses
upon compound application than coexpression with wild-type
TRPML1. We found that coexpression of TRPML1(NC) indeed
showed higher response levels upon agonist application than
did coexpression with wild-type TRPML1 (Figures 7D–7F).
Generally, these data corroborate the hypothesis that interactionChemistry & Biology 17, 135with TRPML1 generates TRPML3/TRPML1 heteromers that
preferentially localize to intracellular compartments. The ques-
tion is whether this interaction is relevant in cells that natively
express TRPML3.
We sought to further confirm this regulation by suppressing
the expression of native TRPML1 in epidermal melanocytes.
For this, we used a specific shRNA that is able to strongly
down-regulate overexpressed human TRPML1 (Samie et al.,
2009; Figure 7G). In native cells, however, overexpression of
shRNA to TRPML1 did not affect responsiveness (Figure 7H),
indicating that native TRPML1 expression is either too strong
for efficient suppression with shRNA or that the lack of TRPML3
responsiveness in native cells is due to additional mechanisms
independent of TRPML1. The latter hypothesis is supported by–148, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 143
Figure 7. Effects of Modulating TRPML1 Expression and Modulation of Endocytosis on TRPML3 Agonist Responses
(A) Protein sequence comparison of the N and C termini of TRPML channels. Different lysosomal targeting sequence (LTS) motifs are labeled in green.
(B) Simple drawing of the TRPML1 topology indicating the positions of the LTS motifs that were removed in mutant (-LTS) TRPML1 isoforms.
(C) Representative laser scanning micrograph of HEK293 cells overexpressing TRPML1(NC)-YFP lacking N- and C-terminal LTS motifs. Please see Figure 5A for
comparison with wild-type TRPML1 localization. The plasma membrane is visualized with pan-Cadherin (pan-Cad) antibodies (red). Scale bar = 10 mm.
(D–F) Ca2+-imaging results showing relative [Ca2+]i increases after application of compound SF-23, SF-22, or SN-2 in HEK293 cells coexpressing TRPML3 with
TRPML1, with TRPML1(NC) or with various controls. Shown are mean values ± SEM (nR 3 independent experiments with 20–30 cells each).
(G) Confocal micrographs of HEK293 cells overexpressing wild-type TRPML1-YFP or TRPML1-YFP mutant (C1218T, silent mutation disrupting the shRNA
binding region) in presence or absence of TRPML1 shRNA (shRNA 1208). Only wild-type TRPML1, but not the mutant is specifically down-regulated by shRNA
1208. Scale bar = 50 mm.
(H) Ca2+-imaging results showing [Ca2+]i increases in primary human epidermal melanocytes (HEM, black = nontransfected (NT)), and HEMs cotransfected with
shRNA to TRPML1 (red) upon application of selected TRPML3 activating compounds from 5 different scaffolds (SF-11, -21, -22, -31, -41, and -51) and singleton
SN-2 at 30 mM (mean values ± SEM, nR 3 independent experiments with 5–10 cells). An expression vector for YFP was cotransfected with the shRNA for iden-
tification of the transfected cells.
(I) Ca2+-imaging results showing changes in [Ca2+]i in HEMs transfected with either Dyn, DynK44A, or YFP (control) in response to application of TRPML3-acti-
vating compounds SF-11, SF-21, SF-51, and singleton SN-2 at a concentration of 30 mM, each (mean values ± SEM; nR 3 independent experiments with 20–30
cells).
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TRPML3 in vivo only accounts for a small fraction of the channel
populations (Kim et al., 2009; Zeevi et al., 2009).
Effect of Endocytosis Modulation on TRPML3
Compound Responses
Beside a possible regulation of TRPML3 plasma membrane
localization by TRPML1, other plausible regulation mechanisms
have recently been explored (Kim et al., 2009). The authors found
that a dominant-negative dynamin mutant (DynK44A) increased
plasma membrane expression of TRPML3, which led them to
conclude that TRPML3 recycles between the plasma membrane
and intracellular compartments via a dynamin-dependent endo-144 Chemistry & Biology 17, 135–148, February 26, 2010 ª2010 Elsecytic pathway. On the basis of this finding, we would expect that
increase of dynamin-mediated endocytosis would decrease the
number of TRPML3 channels in the plasma membrane, whereas
inhibition of dynamin would increase responsiveness to TRPML3
activators. To test this hypothesis, we coexpressed wild-type
dynamin with TRPML3 in HEK293 cells. We indeed found
a reduction in response to weak and strong TRPML3 activators,
compared with control experiments (SF-24 and SN-2; Fig-
ure S6). When we repeated the experiment in epithelial melano-
cytes, we also found a reduction of the response to SN-2 (Fig-
ure 7I), indicating that the responding channel is affected by
increased endocytosis. Conversely, when we coexpressed the
dominant-negative K44A dynamin isoform with TRPML3 wevier Ltd All rights reserved
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When we expressed the K44A isoform in epithelial melanocytes,
we did not, however, detect any significant changes in response
levels to TRPML3 activating compounds (Figure 7I). The fact that
neither TRPML1 knockdown nor block of dynamin-mediated
endocytosis appeared to significantly modulate responses in
cells natively expressing TRPML3, suggested that these manip-
ulations were either not strong or sufficient enough or that alter-
native mechanisms are involved in the regulation of TRPML3
function.
DISCUSSION
In this study, we identified and confirmed 53 selective small
molecule activators of TRPML3. Although the majority of the
compounds were sulfonamides, they displayed a wide variety
of structures belonging to nine chemical scaffolds and 19 single-
tons. We further analyzed 15 compounds in detail and found
that their maximal activation capacities varied over an order of
magnitude, indicating a variety of potential mechanisms of
affecting TRPML3 activity. The combined collection of so many
different but efficient activators of a single TRP channel is
unprecedented, which provides an unparalleled set of novel
tools to study the biophysical and physiological features of
TRPML3.
Toward these goals, we analyzed the relationship between
compound activation and regulation of the channel by extracel-
lular Na+. A previous study implicated Na+ as a TRPML3 regu-
lator, but not as a blocker per se (Kim et al., 2007). We found
this feature intriguing because TRPML3 has been reported in
the apical plasma membrane of sensory hair cells in the mouse
cochlea during the first neonatal week (Atiba-Davies and Noben-
Trauth, 2007; Di Palma et al., 2002; van Aken et al., 2008), a time
period that coincides with changes of the ionic composition of
the endolymph, the extracellular solution of the cochlear scala
media into which the mechanosensitive stereociliary hair
bundles protrude. Between birth and P5, when the expression
of TRPML3 at the base of hair cell stereocilia is at its highest,
the endolymphatic [Na+] drops from 36 mM to 4.1 mM. Adult
murine endolymph is composed of 2.8 mM Na+ and 202 mM
K+ (Yamasaki et al., 2000). When we exposed TRPML3-express-
ing HEK293 cells to endolymph-like solutions, we detected
a robust inward rectifying current whose maximal amplitudes
were dependent on the extracellular Na+ concentration. Specif-
ically, TRPML3 activated when [Na+] dropped below 20 mM and
its activation was gradually more efficient when the [Na+] was
stepwise lowered to 2 mM, which elicited the maximal response.
This concentration range matches the [Na+] concentration
changes during the neonatal maturation of cochlear endolymph
(Yamasaki et al., 2000), and it raised two questions: first, whether
lowering extracellular [Na+] affects compound responsiveness
and, second, whether neonatal hair cells are responsive to ELS
and compound activation.
To answer the first question, we applied compounds in low
extracellular [Na+], and we detected a strong synergism that
was obvious both with low-efficient compounds as well as with
compounds that elicited strong responses. Our data confirmed
that Na+ is not a blocker of TRPML3 per se because compound
activation happens in high extracellular Na+ (138 mM). Neverthe-Chemistry & Biology 17, 135less, lowering [Na+] to 2 mM led to a 10-fold increase of the
current response, a clear indication that the two activation mech-
anisms are cooperatively acting on TRPML3.
To investigate the second question of whether cochlear hair
cells are able to utilize TRPML3 to detect changes of the
ionic composition of endolymph, we exposed acutely isolated
cochlear hair cells to ELS, compound activators, and to combi-
nations of both. To our surprise, we were not able to elicit any
TRPML3 responses when we exposed P4-P6 cochlear hair cells
to ELS and to some of the most effective TRPML3 activators,
even at very high compound concentrations. Application of
compounds in ELS also did not elicit responses from sensory
hair cells. Because the temporal expression pattern of TRPML3
in the rat cochlea could differ from the mouse, we also tested
a total of 145 inner and outer hair cells from younger (P0) and
older (up to P12) animals by puffing ELS onto their apical surface,
but we did not observe specific responses (data not shown).
Albeit puzzling, these results reveal a number of interesting
scenarios. One possibility is that TRPML3 is not present in
hair cell plasma membranes. If this were the case, the vari-
tint-waddler phenotype (Di Palma et al., 2002; Grimm et al.,
2009) would have to be caused by mislocalization of the con-
stitutively active TRPML3 Va isoform to the plasma membrane.
A second possibility is that the activators that we identified act
only on homomeric TRPML3 channels and that these homo-
meric channels only form when TRPML3 is overexpressed.
In hair cells, TRPML3 would be a subunit of a more complex
channel of unknown composition that is nonresponsive to the
compounds. Third, plasma membrane–bound TRPML3 could
be very tightly regulated and endocytotic removal of the
channel from the plasma membrane renders hair cells nonre-
sponsive.
A second cell type that natively expresses TRPML3 is epi-
dermal melanocytes, which are more suitable for in vitro inquires
than sensory hair cells. When we tested primary epidermal
melanocytes, we were unable to evoke TRPML3 responses
with all compounds except for SN-2, which at elevated concen-
trations was able to prompt a significant increase of the intracel-
lular Ca2+ concentration. Because primary epidermal melano-
cytes can be transfected with expression plasmids, we first
tested whether melanocytes have an inherent inability to
respond to activators. This is not the case because when we
transfected human melanocytes with a TRPML3 expression
vector, we were able to measure with calcium indicator dyes
robust responses of the transfected cells to compounds. A sec-
ond question is whether TRPML3 is modified or regulated in
native cell types rendering the channel nonresponsive. Phos-
phorylation or other forms of posttranslational modification
could affect overexpressed TRPML3 channels. In such cases,
we would not be able to detect strong responses to TRPML3
activators. It is therefore unlikely that TRPML3 in melanocytes
is nonresponsive because of posttranslational modifications.
Another form of regulation, heteromerization, relies on the
endogenous expression of other channel proteins capable of
interacting with TRPML3, resulting in heteromeric channels
that might localize to intracellular compartments or do not
respond to compound and ELS activation. We detected expres-
sion of TRPML1 and TRPML2 mRNA in the inner ear and in
epidermal melanocytes, which would make heteromerization–148, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 145
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Small Molecule Activators of TRPML3with TRPML1 or TRPML2 a possibility in these cell types. Never-
theless, epidermal melanocytes expressing shRNA to TRPML1
did not display increased responses to TRPML3 activators
when compared with control cells. This lack of responsiveness
could be due to incomplete inhibition of TRPML1 expression,
despite the efficacy of the knockdown in heterologous expres-
sion situations (Miedel et al., 2008; Samie et al., 2009). An alter-
native interpretation would be that the influence of TRPML1 on
TRPML3 is rather limited because the two proteins may be traf-
ficked differently in native cells. Indeed, endogenous TRPML
channels only partially colocalize, and coimmunoprecipitation
revealed that only a limited fraction of endogenous TRPML3
interacts with endogenous TRPML1 (Kim et al., 2009; Zeevi
et al., 2009). In addition, TRPML3 has been put forward as autor-
egulator of autophagy (Kim et al., 2009), which could very much
limit the occurrence of TRPML3 in the plasma membrane of cells
that natively express TRPML3. When we coexpressed dynamin
with TRPML3 in HEK293 cells, we indeed found a reduced
response to TRPML3 activators. Coexpression of the domi-
nant-negative K44A mutant of dynamin with TRPML3 resulted
in small response increases. Although these data are in favor
of recent evidence that TRPML3 recycles between the plasma
membrane and intracellular compartments, and that autophagy
might play a role as a tight regulator of plasma membrane
TRPML3, overexpression of the K44A dynamin mutant in human
skin melanocytes had no effect on native TRPML3 activator
responsiveness.
The sum of differences observed between overexpression
studies and expression in primary cells highlight the limitations
of cell culture experiments to study trafficking and physiology
of TRPML3. Nevertheless, in conclusion, our data show that
melanocytes and sensory hair cells do not express activator-
responsive TRPML3 in their plasma membrane. Nonresponsive-
ness could be a result of total absence of the channel protein
from the surface of the cells or that TRPML3 exists primarily as
a subunit of heteromeric channels in vivo.
SIGNIFICANCE
In this study, we identified 53 compounds that selectively
activate TRPML3 with EC50 values of <5 mM. The identified
activators are surprisingly diverse and can be classified
into nine different chemical scaffolds and 19 singletons.
The compounds are highly specific for TRPML3, and
because they activate the channel with different kinetics
andmaximal response levels, we content that they comprise
an unprecedented collection of tools to investigate activa-
tion mechanisms of TRPML3. The observation that
combining compound activators with lowering of extracyto-
solic [Na+] strongly potentiated the individual responses re-
vealed that at least two different mechanisms cooperatively
control TRPML3 activity. They further reveal a wide dynamic
range of channel activity, suggesting that TRPML3 response
features are stimulus dependent. When we tested the
compounds on cells that natively express TRPML3, we
uncovered that sensory hair cells failed to respond and
that epidermal melanocytes showed only weak or no
responses. These results suggest that TRPML3 in native
cells is either not present in the plasma membrane or that146 Chemistry & Biology 17, 135–148, February 26, 2010 ª2010 Elsethe protein heteromerizes with other subunits in hair cells
and epidermal melanocytes, leading to channels that are
not or only weakly responsive to the compounds identified
in this screen.EXPERIMENTAL PROCEDURES
Plasmid Constructs and Cells
All cultured cells were grown and maintained in a standard humidified 37C
incubator, with 5% CO2. HEK293 and NIH 3T3 cells were maintained in
DMEM (Invitrogen), supplemented with 10% fetal bovine serum (Invitrogen),
100 mg/ml penicillin, and 100 mg/ml streptomycin. HEK293 cells stably
expressing human TRPML3 and danio rerio TRPN1 (as YFP-fusion proteins)
were selected from transfected cells using G418 (geneticin, Sigma-Aldrich)
at a final concentration of 0.8 mg/ml and subcloned twice from clearly isolated
colonies. Expression vectors were based on pcDNA3.1 (Invitrogen). Mutants
were generated from wild-type cDNA templates using QuikChange Site-
Directed Mutagenesis Kit (Stratagene) and were verified by sequencing both
strands entirely. For calcium imaging and electrophysiological experiments
in HEK293 cells, all plasmid constructs were transiently expressed in
HEK293 cells with the use of Genejammer (Stratagene) and were measured
24 hr after transfection. In none of the experiments conducted for this study
did we observe any anomalous effect of tags on TRPML channel localization
and function.
Normal neonatal human epidermal melanocytes (kindly provided by
Dr. P. Khavari, Stanford University) were cultured in medium 254 supple-
mented with HMGS (Cascade Biologic). Using the Amaxa Nucleofector
(NHEM-Neo Nucleofector Kit, program U-016), 53 105 cells were transfected
with 5 mg of plasmid DNA per experiment.High-Throughput Screen
As part of the Molecular Libraries Probe Production Network (MLPCN; http://
mli.nih.gov/mli/) initiative, the high-throughput screening campaign was
executed on the automated Kalypsys robotic platform located at the Scripps
Research Institute Molecular Screening Center (SRIMSC; Jupiter, FL).
Screening results for the TRPML3 (PubChem AID 1448) and TRPN1 (PubChem
AID 1424) agonist primary screens, and all subsequent assays within the
screening campaign have been deposited into PubChem. Both primary assays
were screened against the full MLPCN screening library, which consisted of
217,969 compounds.
The NIH Molecular Libraries Small Molecule Repository (MLSMR, USA)
provided compound collections for the primary and initial confirmation assays
(dissolved at concentrations up to 10 mM in DMSO). Reference and ordering
information for all compounds can be obtained from PubChem website
(http://pubchem.ncbi.nlm.nih.gov/) by conducting queries with the PubChem
substance identifier (SID). For follow-up studies, compound SF-11 was
obtained from Maybridge. Compounds SF-21, SF-31, SF-41, and SN-1 were
obtained from Asinex Ltd.. Compounds SF-22 and SF-23 were purchased
from Enamine, compounds SF-24, SF-32, and SF-51 were obtained from
ChemBridge, and compounds SF-33, SF-61, and SN-2 were obtained from
Specs. Compounds SF-71 and SF-81 were purchased from ChemDiv and
Key Organics, respectively. All commercially obtained compounds were veri-
fied by liquid chromatography-mass spectrometry. Stock solutions of the
compounds of 10 mM in DMSO were stored in small aliquots at 80C.
The assay protocols for both TRPML3 and TRPN1 were identically matched.
Cells were diluted in growth medium and dispensed into 1536-well black-wall,
clear-bottom plates (Greiner Bio-One) at a concentration of 1500 cells/well,
and were allowed to attach for 23 hr at 37C. Screen Quest Fluo-8 No Wash
Calcium mix (ABD Bioquest), prepared according to the manufacturer’s
instructions, was dispensed into each well. After incubating for 1 hr at 37C,
and 30 min at room temperature, an initial basal fluorescent measurement
for 5 s was performed (470–495 nm excitation and 515–575 nm emission) using
the FLIPRTETRA fluorescence reader (Molecular Devices). Test compounds
(2.99 mM final concentration), DMSO alone (carrier control), or Carbachol
(87 mM final concentration, as positive control to elicit calcium influx) was
added to sample or appropriate control wells, respectively. Then a real-timevier Ltd All rights reserved
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120 s of the assay.
The data from each campaign were normalized with basal fluorescence by
dividing the maximum fluorescence over the entire real time reading by the
initial basal fluorescence. The percentage of activation for each compound
was determined using calculated ratios on a per-plate basis as follows:
percentage of activation = 1003 (test_compound  low_control) / (high_con-
trol low_control), Where test compound indicates the ratio of fluorescence of
wells containing test compound, low control indicates the median average
ratio of fluorescence of wells containing DMSO, and high control indicates
the median average ratio of fluorescence of wells containing carbachol.
HTS Hit Selection and Activity Cutoff Criteria
To determine agonistic compounds in each primary screen, two values were
calculated: (1) the average percentage activation of all compounds tested
and (2) three times their standard deviation (Hodder et al., 2003). The sum of
these two values was used as a cutoff parameter—that is, any compound
that exhibited greater percentage of activation than the cutoff value was
considered active. Z’ values were determined to monitor assay quality and
were calculated as described elsewhere (Zhang et al., 1999). Assay plates
were rejected and rerun if Z’ was less than 0.5.
Confirmation, Counterscreening, and Dose-Response Assays
Test compounds active in the primary screening campaign were subsequently
confirmed using the same assay protocol and hit cutoff value as used in
the primary campaign, except that compounds were tested in triplicate. All
confirmation and counterscreen assay data has been uploaded to the
PubChem website (AID 1526: TRPML3 hit confirmation; AID 1525: TRPN1
counterscreen).
The potency of compounds that passed confirmation and counterscreening
was determined using dose-response assays and EC50 values were calculated
from the resultant data. A 10-point dose-response curve with a 1:3 dilution
series from 29.9 mM to 1.5 nM was used, with compounds being tested in trip-
licate. Compounds exhibiting an EC50 value less than 10 mM were considered
active. Dose-response assays were also performed against TRPN1 to confirm
that compounds identified as TRPML3 agonists were selective (PubChem AID
1562: TRPML3 dose-response determinations; AID 1682: TRPN1 dose-
response determinations). Data were analyzed using MDL Assay Explorer
(version 3.1, Symyx Solutions). Curve fitting was performed with a four-param-
eter equation describing a sigmoidal dose-response curve with adjustable
baseline. EC50 values were generated from fitted curves by solving for the
X-intercept at the 50% inhibition level of the Y-intercept.
Calcium Imaging and Electrophysiology
Measurements of [Ca2+]i with the fluorescent indicators fura-2-AM (Invitrogen)
was performed using a monochromator-based imaging system (iMIC platform
and Polychrome V monochromator, TILL Photonics). HEK293 cells, plated
onto glass coverslips, were loaded with 4 mM fura-2-AM (Invitrogen) in a stan-
dard bath solution (SBS) containing 138 mM NaCl, 6 mM KCl, 2 mM MgCl2,
2 mM CaCl2, 10 mM HEPES, and 5.5 mM D-glucose (adjusted to pH 7.4 with
NaOH).
Whole-cell currents were recorded with an Alembic Instruments VE-2 ampli-
fier with 100% series resistance compensation, and acquired with JClamp
software. The standard bath solution contained 138 mM NaCl, 5.4 mM KCl,
2 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, and 10 mM D-glucose, adjusted
to pH 7.4 with NaOH. The standard pipette solution contained 140 mM
CsCl, 10 mM HEPES, 3 mM ATP-Na, 1 mM BAPTA, and 2 mM MgCl2, adjusted
to pH 7.2. 2-Aminoethyl-diphenyl borate (100 mM) was included in the bath
solution to block gap junctions and had no effect on the expressed channels.
Unless indicated differently, the plots shown were responses to 10 ms voltage
steps (holding potential, +10 mV) between 200 mV and +100 mV in 20 mV
incremental steps, normalized by cell capacitance (pF).
RNA Interference (RNAi)
Specific and efficient RNAi-mediated knock down of endogenous human
TRPML1 expression has been recently reported (Miedel et al., 2008; Samie
et al., 2009). Oligonucleotide 50-GCTACCTGACCTTCTTCCACA-30 (Samie
et al., 2009) was cloned into the shRNA expression vector U6 RNA Pol IIIChemistry & Biology 17, 135(Invitrogen). HEK293 cells were cotransfected with 3 mg of shRNA to human
TRPML1 and 1 mg human TRPML1-YFP plasmid using Genejammer, as
described above. A mutant isoform of TRPML1-YFP (C1218T, silent mutation)
was cotransfected with TRPML1 shRNA as a control to determine efficacy
(Figure S5A). Human epidermal melanocytes were cotransfected with 5 mg
TRPML1 shRNA and 2 mg pcDNA3.1-YFP using Amaxa Nucleofector tech-
nology as described above.
Biotinylation, Western Blots, and Immunocytochemistry
Transfected HEK293 cells were analyzed 15–16 hr after transfection, washed,
and surface biotinylated with Sulfo-NHS-LC-LC-biotin solution (Pierce), as
described elsewhere (Grimm et al., 2007). All samples were then processed
for western blot analysis as described elsewhere (Cuajungco et al., 2006),
and visualized using an anti-GFP monoclonal antibody (JL-8; Clontech).
Detection was performed with IRDye 700- and IRDye 800-conjugated sec-
ondary antibodies (Rockland Immunochemicals, Gilbertsville, PA) and scan-
ning with the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln,
NE). Signal quantification was conducted with Image J software (http://rsb.
info.nih.gov/ij/). Immunocytochemistry with mouse monoclonal pan-Cadherin
CH-19 (Abcam, 1:500) and TRITC-conjugated goat anti mouse IgG1 (Jackson
ImmunoResearch), was performed as described elsewhere (Cuajungco et al.,
2006).
ACCESSION NUMBERS
Screening results for the primary and confirmation screens have been depos-
ited in the PubChem BioAssay database with accession codes AID 1424,
1448, 1525, 1526, 1538, 1562, 1660, 1682, and 1809.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables and six figures and can be
found with this article online at doi:10.1016/j.chembiol.2009.12.016.
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